Levosimendan: beyond its simple inotropic effect in heart failure.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Classic inotropic agents offer limited hemodynamic improvement in heart failure with poor prognosis.
• Calcium (Ca2+) sensitizers represent a novel therapeutic class for heart failure management.

Purpose of the Study:

• To evaluate the efficacy and potential benefits of levosimendan, a Ca2+ sensitizer, in treating decompensated heart failure.
• To explore levosimendan's mechanisms of action, including its inotropic and vasodilatory effects, and potential anti-inflammatory and antiapoptotic properties.

Main Methods:

• Levosimendan's mechanism involves Ca2+ sensitization for inotropic effects.
• Vasodilation is achieved through activation of ATP-sensitive K+ (KATP), Ca2+-activated K+ (KCa2+), and voltage-dependent K+ (KV) channels.
• Pharmacokinetic properties, including the long half-life of its active metabolite OR-1896, contribute to sustained hemodynamic improvement.

Main Results:

• Levosimendan demonstrates both positive inotropic and vasodilatory effects.
• Evidence suggests potential anti-inflammatory and antiapoptotic actions relevant to heart failure pathophysiology.
• Recent clinical trials show disappointing results regarding levosimendan's impact on short- and long-term mortality, with unclear superiority over dobutamine.

Conclusions:

• Levosimimendan is a promising agent for decompensated heart failure, impacting multiple pathophysiological pathways.
• Further research and ongoing trials are necessary to definitively establish levosimendan's superiority over classic inotropic agents in improving survival for severe heart failure patients.